Radiation
Chemoradiotherapy for Esophageal Cancer
This trial tests if adding certain chemotherapy drugs to radiation therapy can better relieve swallowing difficulties and improve quality of life for patients with advanced esophageal cancer who can't undergo surgery. These drugs are commonly used in treatment for esophageal cancer and have shown promising results in various studies.
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Monoclonal Antibodies
Paclitaxel +/− Cixutumumab for Esophageal Cancer
This trial is testing how well paclitaxel (a chemotherapy drug) works with or without cixutumumab (a protein-blocking drug) to treat patients with esophageal or gastroesophageal junction cancer that has spread to other parts of the body.
Popular Filters
Trials for Adenocarcinoma Patients
Monoclonal Antibodies
Sacituzumab + Pembrolizumab + Chemotherapy for Esophageal Cancer
This trial is testing a new combination of drugs for the treatment of advanced stomach, esophageal, or gastroesophageal junction cancer. The trial has two phases to evaluate the safety and effectiveness of
Monoclonal Antibodies
Combination Therapies for Esophageal Cancer
This trial is testing two different combinations of drugs to see which one is safer and more effective for treating advanced stomach, esophageal, or gastroesophageal junction cancer in participants who have not responded
ActivSight Imaging for Esophageal Surgery
This trial uses a device that creates a visual representation of blood flow and tissue perfusion during laparoscopic surgery. It will compare accuracy of the device to naked eye inspection and other imaging techniques.
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Trials for Squamous Cell Carcinoma Patients
Monoclonal Antibodies
Sacituzumab + Pembrolizumab + Chemotherapy for Esophageal Cancer
This trial is testing a new combination of drugs for the treatment of advanced stomach, esophageal, or gastroesophageal junction cancer. The trial has two phases to evaluate the safety and effectiveness of
Monoclonal Antibodies
Combination Therapies for Esophageal Cancer
This trial is testing two different combinations of drugs to see which one is safer and more effective for treating advanced stomach, esophageal, or gastroesophageal junction cancer in participants who have not responded
ActivSight Imaging for Esophageal Surgery
This trial uses a device that creates a visual representation of blood flow and tissue perfusion during laparoscopic surgery. It will compare accuracy of the device to naked eye inspection and other imaging techniques.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Trials for HER2 Positive Patients
Monoclonal Antibodies
Pembrolizumab + Trastuzumab + Chemotherapy for Gastric Cancer
This trial will compare the efficacy of two different treatments for HER2-positive gastric cancer. The first treatment is pembrolizumab in combination with standard chemotherapy, and the second is trastuzumab in combination with standard chemotherapy. The hypothesis of the study is that pembrolizumab is superior to trastuzumab in terms of progression free survival and overall survival.
PARP Inhibitor
Rucaparib + Ramucirumab +/- Nivolumab for Stomach and Esophageal Cancer
This trial is for people with advanced stomach, gastroesophageal, or esophageal cancer who have failed initial chemotherapy. The goal is to see if Rucaparib plus Ramucirumab with or without Nivolumab is more effective than what has been reported for Ramucirumab alone. The trial will have a phase 1 component to determine the recommended dosage, and a phase 2 component to compare the two treatment groups.
Enzyme Inhibitor
Ceralasertib + Trastuzumab Deruxtecan for Solid Tumors
This trial will find the best dose and safety of ceralasertib when given with trastuzumab deruxtecan to treat patients with solid tumors that have a change in the HER2 gene or protein.
Phase 3 Trials
Monoclonal Antibodies
Pembrolizumab + Trastuzumab + Chemotherapy for Gastric Cancer
This trial will compare the efficacy of two different treatments for HER2-positive gastric cancer. The first treatment is pembrolizumab in combination with standard chemotherapy, and the second is trastuzumab in combination with standard chemotherapy. The hypothesis of the study is that pembrolizumab is superior to trastuzumab in terms of progression free survival and overall survival.
Alkylating agents
Chemotherapy + Radiotherapy for Esophageal and Gastric Cancer
This trial is studying how well adding radiotherapy to the usual chemotherapy treatment works compared to the usual treatment alone in treating patients with esophageal and gastric cancer.
Monoclonal Antibodies
Pembrolizumab + Lenvatinib + Chemo for Esophageal Cancer
This trial tests a new combination of drugs and chemotherapy for advanced esophageal cancer. It targets patients whose cancer has spread and who need effective first-line treatment. The treatment works by enhancing the immune system, blocking cancer growth, and killing cancer cells.
Trials With No Placebo
Monoclonal Antibodies
Sacituzumab + Pembrolizumab + Chemotherapy for Esophageal Cancer
This trial is testing a new combination of drugs for the treatment of advanced stomach, esophageal, or gastroesophageal junction cancer. The trial has two phases to evaluate the safety and effectiveness of
Monoclonal Antibodies
Combination Therapies for Esophageal Cancer
This trial is testing two different combinations of drugs to see which one is safer and more effective for treating advanced stomach, esophageal, or gastroesophageal junction cancer in participants who have not responded
ActivSight Imaging for Esophageal Surgery
This trial uses a device that creates a visual representation of blood flow and tissue perfusion during laparoscopic surgery. It will compare accuracy of the device to naked eye inspection and other imaging techniques.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
View More Related Trials
Frequently Asked Questions
Introduction to esophagus cancer
What are the top hospitals conducting esophagus cancer research?
When it comes to cutting-edge clinical trials in the battle against esophagus cancer, several esteemed hospitals are leading the charge. In Houston, the M D Anderson Cancer Center takes the forefront with an impressive 13 ongoing trials dedicated to this challenging condition. Over its history, M D Anderson has contributed to a total of 24 esophagus cancer trials since recording its first trial back in 2003. Moving eastward to New york City, Memorial Sloan Kettering Cancer Center is making significant strides as well. With seven active esophagus cancer trials and a cumulative record of 23 studies, their commitment can be traced back to their earliest recorded trial in 2002.
Heading further north to Saint Louis, Washington University School of Medicine continues its dedication with six active clinical trials for esophagus cancer and a commendable track record of 18 previous studies since initiating their first recorded trial in 2005. On the west coast, the University of California Davis Comprehensive Cancer Center joins this prestigious list by currently conducting five active esophagus cancer trials while having completed eight prior investigations dating back to their inaugural trial in 2011. Similarly on the East Coast at University of Pittsburgh Cancer Institute (UPCI), they have also been actively contributing through five ongoing clinical tests for esophageal conditions; having achieved additional eight examinations since commencing investigation particularly from year2010.
These renowned institutions represent shining beacons of hope for those affected by esophagus cancer and demonstrate incredible advancements made within medical research nationwide. The collective efforts exerted by these top hospitals underscore that every step taken towards understanding this complex disease brings us closer toward improved treatment options and outcomes for patients around the world
Which are the best cities for esophagus cancer clinical trials?
When it comes to esophagus cancer clinical trials, several cities emerge as leading centers for research and treatment options. Houston, Texas leads the way with 30 ongoing trials focusing on various treatments like proton beam radiation therapy, pembrolizumab, and other potential breakthroughs. New york City follows closely behind with 23 active trials examining BMS-986340, different treatment approaches, and pembrolizumab. Los Angeles also plays a significant role in esophagus cancer research with 19 ongoing trials investigating targeted therapies such as Subprotocol C2 (MET exon 14 deletion/mutation), pembrolizumab, berzosertib, among others. These cities showcase their dedication to advancing knowledge and improving outcomes for individuals affected by esophagus cancer through innovative clinical trials.
Which are the top treatments for esophagus cancer being explored in clinical trials?
When it comes to exploring novel treatments for esophagus cancer, clinical trials have shed light on several promising options. At the forefront is pembrolizumab, a well-studied drug currently under investigation in three active trials dedicated to esophagus cancer since its first listing in 2014. Joining this contender is atezolizumab, which has shown potential with two ongoing trials and four all-time studies since being introduced in 2017. Additionally, radiation therapy continues to be explored as an effective treatment option through three active and eighteen all-time esophagus cancer trials since 2002. Finally, a pharmacological study stands out with three current investigations and five total past trials starting from its inception in 2010. These advancements bring hope for improved interventions against esophagus cancer that can make a meaningful difference in patients' lives.
What are the most recent clinical trials for esophagus cancer?
Exciting advancements are being made in the field of esophagus cancer research, with recent clinical trials shedding light on potential breakthroughs. Among these trials is a Phase 2 study investigating the combination of futibatinib, pembrolizumab, and chemotherapy for esophagus cancer patients. Another Phase 1 trial focuses on CA-4948 as a potential treatment option for this type of cancer. Furthermore, a Phase 1/Phase 2 study explores CBP-1019 both as monotherapy and in dose escalation for early-stage esophagus cancer. Additionally, promising results have emerged from a Phase 2 trial involving Devimistat combined with other drugs like HCQ and Gemcitabine. Lastly, another Phase 2 trial examines the efficacy of mFOLFOX6 along with pembrolizumab and propranolol to combat esophageal cancer. These ongoing studies offer hope for improved treatment strategies against this challenging disease.
What esophagus cancer clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of esophagus cancer research. One noteworthy trial, sponsored by EMD Serono Research & Development Institute, Inc., investigated the potential of M1231 and was completed in January 2021. Additionally, City of Hope Medical Center concluded a trial studying Pembrolizumab in April 2019. Notably, Sidney Kimmel Cancer Center at Thomas Jefferson University conducted a Fine-Needle Aspiration study that ended in September 2018. These trials and others carried out by renowned institutions such as M.D. Anderson Cancer Center, Duke University, Merck Sharp & Dohme LLC, and Dana-Farber Cancer Institute shed light on new treatment possibilities for esophagus cancer patients.